If you’re bothered by allergies every spring, you may pop a Benadryl or Claritin most mornings to make the days tolerable.

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients ...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. In 2021, five out of the top 10 selling drugs were ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

New commercial milestones: cadonilimab and ivonescimab added to the National Reimbursement Drug List (NRDL ... treatments such as anti-CD47 monoclonal antibody, antibody drug conjugates ...

In the global arena of biomedicine, Guangzhou's innovative drug companies are rewriting the rules with "hard‑core technology.

New commercial milestones: cadonilimab and ivonescimab added to the National Reimbursement Drug List (NRDL). AK117 (CD47 ... while advancing novel treatments such as anti-CD47 monoclonal antibody, ...

We recently published a list of 10 Firms Defy Market Slump, Record Double-Digit Gains Last Week. In this article, we are ...

The findings reinforce the potential of BRIUMVI in improving patient outcomes for those seeking an alternative to their previous anti-CD20 therapy. Furthermore, the article in CNS DRUGS offers an ...

In mid-April 2025, social media users spread a rumor that U.S. President Donald Trump's administration would end animal ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...